Article Text

PDF
Latest insights in therapeutic options for systemic right ventricular failure: a comparison with left ventricular failure
  1. M M Winter1,
  2. B J Bouma1,
  3. M Groenink1,2,
  4. T C Konings3,
  5. J G P Tijssen1,
  6. D J van Veldhuisen4,
  7. B J M Mulder1,5
  1. 1
    Department of Cardiology, Academic Medical Center, Amsterdam, The Netherlands
  2. 2
    Department of Radiology, Academic Medical Center, Amsterdam, The Netherlands
  3. 3
    Department of Cardiology, VU Medical Center, Amsterdam, The Netherlands
  4. 4
    Department of Cardiology, University Medical Center Groningen, Groningen, The Netherlands
  5. 5
    Department of Cardiology, University Medical Center Utrecht, Utrecht, The Netherlands
  1. Professor Barbara J M Mulder, Academic Medical Center, Department of Cardiology, Meibergdreef 9, 1105 AZ Amsterdam, The Netherlands; b.j.mulder{at}amc.uva.nl

Abstract

The number of adult patients with a systemic right ventricle (RV) is steadily increasing. Survival is relatively good in these patients, but deterioration of the systemic RV seems inevitable. Although therapeutic options for patients with LV failure are well established, their role in patients with systemic RV failure is often undefined. To appreciate the potency of LV failure therapy in patients with a systemic RV, insight into pathophysiology of systemic RV failure and into recent developments in therapeutic research are indispensible. This review provides these insights, and will facilitate and ameliorate therapeutic decision making in patients with a systemic RV.

Statistics from Altmetric.com

Footnotes

  • Funding: This study was supported by an unrestricted educational grant from Novartis Pharma BV.

  • Competing interests: None.

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.